These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 28282887)

  • 21. Effects of sulfation on antithrombin-thrombin/factor Xa interactions in semisynthetic low molecular weight heparins.
    Sissi C; Naggi A; Torri G; Palumbo M
    Semin Thromb Hemost; 2001 Oct; 27(5):483-7. PubMed ID: 11668417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition.
    Ofosu FA; Smith LM; Anvari N; Blajchman MA
    Thromb Haemost; 1988 Oct; 60(2):193-8. PubMed ID: 2851191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of the levels of unfractionated and low-molecular-weight heparins in plasma: their effect on thrombin-mediated feedback reactions in vivo. Preliminary results after subcutaneous injection.
    Hemker HC; Béguin S; Bendetowicz AV; Wielders S
    Haemostasis; 1991; 21(4):258-72. PubMed ID: 1665467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. De novo synthesis of a narrow size distribution low-molecular-weight heparin.
    Chandarajoti K; Xu Y; Sparkenbaugh E; Key NS; Pawlinski R; Liu J
    Glycobiology; 2014 May; 24(5):476-86. PubMed ID: 24626379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of the enzymatic activity of alpha-thrombin by polyanions: consequences on intrinsic activation of factor V and factor VIII.
    Ofosu FA
    Haemostasis; 1991; 21(4):240-7. PubMed ID: 1794749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of UH and LMWH are similar with respect to antithrombin activity.
    Morris TA; Jacobson A; Marsh JJ; Lane JR
    Thromb Res; 2005; 115(1-2):45-51. PubMed ID: 15567452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fucosylated chondroitin sulfate oligosaccharides exert anticoagulant activity by targeting at intrinsic tenase complex with low FXII activation: Importance of sulfation pattern and molecular size.
    Li J; Li S; Yan L; Ding T; Linhardt RJ; Yu Y; Liu X; Liu D; Ye X; Chen S
    Eur J Med Chem; 2017 Oct; 139():191-200. PubMed ID: 28800457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ultrasonic-assisted preparation of a low molecular weight heparin (LMWH) with anticoagulant activity.
    Achour O; Bridiau N; Godhbani A; Le Joubioux F; Bordenave Juchereau S; Sannier F; Piot JM; Fruitier Arnaudin I; Maugard T
    Carbohydr Polym; 2013 Sep; 97(2):684-9. PubMed ID: 23911501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The action of a synthetic pentasaccharide on thrombin generation in whole plasma.
    Béguin S; Choay J; Hemker HC
    Thromb Haemost; 1989 Jun; 61(3):397-401. PubMed ID: 2799755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of poly(acrylic acid) acceleration of antithrombin inhibition of thrombin: implications for the design of novel heparin mimics.
    Monien BH; Cheang KI; Desai UR
    J Med Chem; 2005 Aug; 48(16):5360-8. PubMed ID: 16078853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New antithrombotic oligosaccharides].
    Petitou M; Hérault JP; Bernat A; Driguez PA; Duchaussoy P; Lormeau JC; Herbert JM
    Ann Pharm Fr; 1999 May; 57(3):232-9. PubMed ID: 10427858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The ternary complex of antithrombin-anhydrothrombin-heparin reveals the basis of inhibitor specificity.
    Dementiev A; Petitou M; Herbert JM; Gettins PG
    Nat Struct Mol Biol; 2004 Sep; 11(9):863-7. PubMed ID: 15311268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
    Brieger D; Dawes J
    Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preserving the original heparin structure of a novel low molecular weight heparin by gamma-irradiation.
    Bisio A; De Ambrosi L; Gonella S; Guerrini M; Guglieri S; Maggia G; Torri G
    Arzneimittelforschung; 2001 Oct; 51(10):806-13. PubMed ID: 11715633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure and activity of a new low-molecular-weight heparin produced by enzymatic ultrafiltration.
    Fu L; Zhang F; Li G; Onishi A; Bhaskar U; Sun P; Linhardt RJ
    J Pharm Sci; 2014 May; 103(5):1375-83. PubMed ID: 24634007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heparanase as an Additional Tool for Detecting Structural Peculiarities of Heparin Oligosaccharides.
    Alekseeva A; Urso E; Mazzini G; Naggi A
    Molecules; 2019 Dec; 24(23):. PubMed ID: 31810297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening enoxaparin tetrasaccharide SEC fractions for 3-O-sulfo-N-sulfoglucosamine residues using [(1)H,(15)N] HSQC NMR.
    Beecher CN; Manighalam MS; Nwachuku AF; Larive CK
    Anal Bioanal Chem; 2016 Feb; 408(6):1545-55. PubMed ID: 26758598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heparins: A Shift of Paradigm.
    Hemker HC; Al Dieri R; Béguin S
    Front Med (Lausanne); 2019; 6():254. PubMed ID: 31803745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
    Meddahi S; Bara L; Fessi H; Samama MM
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The structure of synthetic oligosaccharides in relation to factor IXa inhibition.
    Hérault JP; Gaich C; Bono F; Driguez PA; Duchaussoy P; Petitou M; Herbert JM
    Thromb Haemost; 2002 Sep; 88(3):432-5. PubMed ID: 12353072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.